MUKILTEO, Wash., Sept. 8, 2008 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) will hold a conference call to discuss recent findings demonstrating the value of its HemeScan(tm) test for Leukemia patients. Company management, including Dr. Mansoor Mohammed, President and CEO of Combimatrix Molecular Diagnostics and Dr. Shelly Gunn, Medical Director of Combimatrix Molecular Diagnostics, will host this call and will make a short presentation, followed by Q&A. Combimatrix Molecular Diagnostics is a wholly owned subsidiary of CombiMatrix Corporation.
